Table 3.
DEXA results at 12 weeks from baseline according to the groups (PPS).
| BB-3 Group (n = 42) | Placebo Group (n = 41) | ||
|---|---|---|---|
| Body fat mass, g | V2 | 25,446.90 ± 4405.20 | 26,163.00 ± 3809.42 |
| V5 | 24,859.86 ± 4382.83 | 26,098.63 ± 4022.56 | |
| V5-V2 | −587.05 ± 1004.42 | −64.37 ± 933.76 | |
| p-value | 0.0005 1 | 0.6613 1 | |
| Difference V5-V2 (Tx-Px) | −522.68 ± 970.17 | ||
| LS mean difference 5 | −528.56 | ||
| p-value | 0.0170 3 | ||
| Body fat percentage (%) | V2 | 36.60 ± 6.67 | 38.73 ± 6.14 |
| V5 | 36.28 ± 6.77 | 38.64 ± 6.25 | |
| V5-V2 | −0.32 ± 1.26 | −0.09 ± 0.97 | |
| p-value | 0.1097 1 | 0.5431 1 | |
| Difference V5-V2 (Tx-Px) | −0.22 ± 1.12 | ||
| LS mean difference 5 | −0.23 | ||
| p-value | 0.3760 3 | ||
| Fat-free mass, g | V2 | 47,094.50 ± 8707.45 | 44,334.07 ± 8532.53 |
| V5 | 46,622.79 ± 8539.42 | 44,362.80 ± 8454.12 | |
| V5-V2 | −471.71 ± 1500.65 | 28.73 ± 840.49 | |
| p-value | 0.0916 2 | 0.8279 1 | |
| Difference V5-V2 (Tx-Px) | −500.45 ± 1220.14 | ||
| p-value | 0.1172 4 | ||
1 p-value for the paired t-tests, 2p-value for the Wilcoxon signed rank test, 3 p-value for ANCOVA adjusted for baseline values and sex, 4 p-value for the Wilcoxon rank sum test, 5 ANCOVA results adjusted for baseline values and sex. Tx: BB-3, Px: placebo, ANCOVA: analysis of covariance, PPS: per protocol set. Data are presented as the mean ± SD. Abbreviations: V2: Visit 2, V5: Visit 5.